Shattuck Labs, Inc. (NASDAQ:STTK) Q3 2023 Earnings Call Transcript

Gil Blum: Excellent. Very helpful. And my follow-on is, can you get a sense of the behavior of the non-responding patients in stable diseases kind of – in immuno-oncology, a lot of times you see at least prolonged stable diseases. Thank you.

Taylor Schreiber: Sure. It’s too early to say too much. As Lini alluded to, they were out of the balance of eight patients four had a best response of progressive disease and four had a best response of stable disease of varying lengths of time. And I think we need to wait and see the full data set from the initial 20-patient cohort before we can make any assertions about whether those patients with stable disease had stable disease for longer than you would expect in a patient population like this.

Gil Blum: All right, excellent. Thanks for taking our questions.

Taylor Schreiber: Thanks, Gil.

Operator: Thank you. This concludes the Q&A session of the call. At this time, I would like to turn the call back over to Taylor Schreiber, Chief Executive Officer of Shattuck Labs for closing remarks.

Taylor Schreiber: Thank you, operator, and thank you all for joining the Shattuck Labs’ Third Quarter 2023 Financial Results and Business Update Conference Call. We appreciate your continued interest in Shattuck and we look forward to updating you on our milestones later this year. Thank you.

Operator: This concludes today’s conference call. Thank you for participating. You may now disconnect. Have a wonderful day.